Glucagon Market to Reach $616.4 Million by 2035

Glucagon market was valued at $350.8 million in 2025 and is projected to reach $616.4 million by 2035, growing at a CAGR of 5.9% during the forecast period (2026-2035). The growing burden of diabetes across major healthcare systems continues to represent a primary structural driver for the glucagon market. According to US Center of Disease Control and Prevention indicate that more than 40 million individuals in the US are living with diabetes, reflecting sustained growth in patients requiring intensive glucose management and emergency treatment preparedness. Updated epidemiological findings also show that total diabetes prevalence among adults reached 15.8 percent during 2021–2023, indicating a large population exposed to hypoglycemia risk associated with insulin therapy and strict glycemic control.

Browse the full report description of “Glucagon Market Size, Share & Trends Analysis Report by Product Type (Injectable and Nasal), by Application (Emergency Kits, General Use, Diagnostics & Motility, and Others), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/glucagon-market

Rising diagnosis rates and expanding screening initiatives are increasing awareness of severe hypoglycemia, encouraging healthcare providers to integrate ready-to-use glucagon products into treatment plans. Clinical practice guidelines emphasizing rapid intervention outside hospital settings are further supporting adoption of nasal and injectable rescue therapies. Increased disease prevalence is influencing pharmacy stocking strategies and procurement decisions, particularly in regions with established diabetes management frameworks. As healthcare systems focus on reducing emergency complications and hospitalization rates, demand for accessible glucagon formulations continues to strengthen.

Innovation Leaders Transforming the Glucagon Market

The key players in the eHealth market include Eli Lilly and Company, Amphastar Pharmaceuticals, Inc., Novo Nordisk A/S, Xeris Biopharma Holdings, Inc., Fresenius SE & Co. KGaA (Fresenius Kabi), among others. These companies are advancing innovation in glucagon therapies through the development of ready-to-use injectable and nasal delivery formats, improved formulation stability, and simplified administration mechanisms, supporting faster response during hypoglycemic emergencies and enhancing treatment accessibility across healthcare and homecare settings.

• In March 2025, Xeris received approval for a supplemental application enabling Gvoke VialDx (glucagon) to be used as a diagnostic aid, expanding its application beyond hypoglycemia treatment.
• In July 2024, dasiglucagon received European authorization following a positive regulatory opinion, introducing a next-generation rescue therapy option for severe hypoglycemia.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Product Type
  • By Application
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Eli Lilly and Company, Amphastar Pharmaceuticals, Inc., Novo Nordisk A/S, Xeris Biopharma Holdings, Inc., Fresenius SE & Co. KGaA (Fresenius Kabi),, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Glucagon Market Report Segment

By Product Type

• Injectable
• Nasal

By Application

• Emergency Kits
• General Use
• Diagnostics & Motility
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Glucagon Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/glucagon-market